A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

NCT05872269 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

1500

Enrollment

INDUSTRY

Sponsor class

Conditions

NAFLD
Obesity
Type 2 Diabetes
Dyslipidemias
Metabolic Syndrome

Interventions

DRUG: Saroglitazar

Sponsor

Zydus Lifesciences Limited